19 June 2013
Keywords: transition, fully, enrolled, gastrin, analog, trial, canada
Article | 09 February 2009
Canada's Transition Therapeutics has completed patient enrolment for a Phase II study of its gastrin analog, TT-223, in patients with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 February 2009
18 June 2013
© 2013 thepharmaletter.com